drugset / Trial / NCT04074759
FPT155 in Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of FPT155 as monotherapy in patients with advanced solid tumors.
Timeline
- Start
- 2018-10-18
- Primary completion
- 2021-08-10
- Completion
- 2021-08-10
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FPT155 | Protein / enzyme biologic | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |